MNPR Stock Price, Chart, Stats & News
MNPR chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -0.01% |
ROE | -0.06% |
D/E | 0.00x |
Interest coverage ratio | – |
MNPR valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -35.59x |
P/FCF | -33.38x |
P/OCF | -35.59x |
PEG | 0.96x |
EV multiple | -3096.04x |
About
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers.
Similar securities
Based on sector and market capitalization
